These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 32019703)

  • 21. Early impact of sequential introduction of 7-valent and 13-valent pneumococcal conjugate vaccine on IPD in Israeli children <5 years: an active prospective nationwide surveillance.
    Ben-Shimol S; Greenberg D; Givon-Lavi N; Schlesinger Y; Somekh E; Aviner S; Miron D; Dagan R
    Vaccine; 2014 Jun; 32(27):3452-9. PubMed ID: 24690148
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Post licensure surveillance of influenza vaccines in the Vaccine Safety Datalink in the 2013-2014 and 2014-2015 seasons.
    Li R; Stewart B; McNeil MM; Duffy J; Nelson J; Kawai AT; Baxter R; Belongia EA; Weintraub E
    Pharmacoepidemiol Drug Saf; 2016 Aug; 25(8):928-34. PubMed ID: 27037540
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Coadministration of 13-valent pneumococcal conjugate and quadrivalent inactivated influenza vaccines in adults previously immunized with polysaccharide pneumococcal vaccine 23: a randomized clinical trial.
    Thompson AR; Klein NP; Downey HJ; Patterson S; Sundaraiyer V; Watson W; Clarke K; Jansen KU; Sebastian S; Gruber WC; Scott DA; Schmöele-Thoma B
    Hum Vaccin Immunother; 2019; 15(2):444-451. PubMed ID: 30303436
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 13-valent pneumococcal conjugate vaccine given with meningococcal C-tetanus toxoid conjugate and other routine pediatric vaccinations: immunogenicity and safety.
    Martinón-Torres F; Gimenez-Sanchez F; Gurtman A; Bernaola E; Diez-Domingo J; Carmona A; Sidhu M; Sarkozy DA; Gruber WC; Emini EA; Scott DA;
    Pediatr Infect Dis J; 2012 Apr; 31(4):392-9. PubMed ID: 22301472
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine pediatric vaccinations in Canada.
    Vanderkooi OG; Scheifele DW; Girgenti D; Halperin SA; Patterson SD; Gruber WC; Emini EA; Scott DA; Kellner JD;
    Pediatr Infect Dis J; 2012 Jan; 31(1):72-7. PubMed ID: 21960186
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunogenicity and safety of a booster dose of the 13-valent pneumococcal conjugate vaccine in children primed with the 10-valent or 13-valent pneumococcal conjugate vaccine in the Czech Republic and Slovakia.
    Urbancikova I; Prymula R; Goldblatt D; Roalfe L; Prymulova K; Kosina P
    Vaccine; 2017 Sep; 35(38):5186-5193. PubMed ID: 28797727
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness of the seven-valent and thirteen-valent pneumococcal conjugate vaccines in England: The indirect cohort design, 2006-2018.
    Andrews N; Kent A; Amin-Chowdhury Z; Sheppard C; Fry N; Ramsay M; Ladhani SN
    Vaccine; 2019 Jul; 37(32):4491-4498. PubMed ID: 31272872
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Nuorti JP; Whitney CG;
    MMWR Recomm Rep; 2010 Dec; 59(RR-11):1-18. PubMed ID: 21150868
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term Impact of Pneumococcal Conjugate Vaccines on Invasive Disease and Pneumonia Hospitalizations in Indigenous and Non-Indigenous Australians.
    Meder KN; Jayasinghe S; Beard F; Dey A; Kirk M; Cook H; Strachan J; Sintchenko V; Smith H; Giele C; Howden B; Krause V; Mcintyre P
    Clin Infect Dis; 2020 Jun; 70(12):2607-2615. PubMed ID: 31388670
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Surveillance of adverse events following the introduction of 13-valent pneumococcal conjugate vaccine in infants, and comparison with adverse events following 7-valent pneumococcal conjugate vaccine, in Victoria, Australia.
    Littlejohn ES; Clothier HJ; Perrett KP; Danchin M
    Hum Vaccin Immunother; 2015; 11(7):1828-35. PubMed ID: 26075435
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Late onset of injection site reactions after vaccination with the 13-valent pneumococcal conjugate vaccine in adult study populations.
    Juergens C; Trammel J; Shoji Y; Patterson S; Watson W; Webber C; Gruber WC; Scott DA; Schmoele-Thoma B
    Hum Vaccin Immunother; 2018; 14(8):1948-1956. PubMed ID: 29543583
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness of the 13-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in South African children: a case-control study.
    Cohen C; von Mollendorf C; de Gouveia L; Lengana S; Meiring S; Quan V; Nguweneza A; Moore DP; Reubenson G; Moshe M; Madhi SA; Eley B; Hallbauer U; Finlayson H; Varughese S; O'Brien KL; Zell ER; Klugman KP; Whitney CG; von Gottberg A;
    Lancet Glob Health; 2017 Mar; 5(3):e359-e369. PubMed ID: 28139443
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of the 13-Valent Pneumococcal Conjugate Vaccine Among Adults: A Systematic Review and Meta-analysis.
    Vadlamudi NK; Chen A; Marra F
    Clin Infect Dis; 2019 Jun; 69(1):34-49. PubMed ID: 30312379
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to 23-valent pneumococcal polysaccharide in immunocompetent adults: A systematic review and meta-analysis.
    Vadlamudi NK; Parhar K; Altre Malana KL; Kang A; Marra F
    Vaccine; 2019 Feb; 37(8):1021-1029. PubMed ID: 30685252
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Febrile seizures after 2009 influenza A (H1N1) vaccination and infection: a nationwide registry-based study.
    Bakken IJ; Aaberg KM; Ghaderi S; Gunnes N; Trogstad L; Magnus P; Håberg SE
    BMC Infect Dis; 2015 Nov; 15():506. PubMed ID: 26553258
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment of functional antibacterial opsonophagocytic antibodies elicited by 13-valent pneumococcal conjugate vaccine administered concomitantly with trivalent influenza vaccine in a randomized clinical trial in adults aged ≥65 years.
    Schwarz TF; Schmoele-Thoma B
    Vaccine; 2013 Jan; 31(2):291-4. PubMed ID: 23123107
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 13-Valent pneumococcal conjugate vaccine in older children and adolescents either previously immunized with or naïve to 7-valent pneumococcal conjugate vaccine.
    Frenck R; Thompson A; Senders S; Harris-Ford L; Sperling M; Patterson S; Devlin C; Jansen KU; Gruber WC; Emini EA; Scott DA; Gurtman A
    Pediatr Infect Dis J; 2014 Feb; 33(2):183-9. PubMed ID: 24136369
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Invasive Pneumococcal Disease Following the Introduction of 13-Valent Conjugate Vaccine in Children in New York City From 2007 to 2012.
    Farnham AC; Zimmerman CM; Papadouka V; Konty KJ; Zucker JR; Nattanmai GV; Jose S; Rosen JB
    JAMA Pediatr; 2015 Jul; 169(7):646-52. PubMed ID: 25938798
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Kawasaki Disease Following the 13-valent Pneumococcal Conjugate Vaccine and Rotavirus Vaccines.
    Kamidani S; Panagiotakopoulos L; Licata C; Daley MF; Yih WK; Zerbo O; Tseng HF; DeSilva MB; Nelson JC; Groom HC; Williams JTB; Hambidge SJ; Donahue JG; Belay ED; Weintraub ES
    Pediatrics; 2022 Dec; 150(6):. PubMed ID: 36349537
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In the heat of a signal: responding to a vaccine safety signal for febrile seizures after 2010-11 influenza vaccine in young children, United States.
    Broder KR; Martin DB; Vellozzi C
    Vaccine; 2012 Mar; 30(11):2032-4. PubMed ID: 22361305
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.